Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales ...

EGOT winner Whoopi Goldberg railed against an ad that's circulating on social media with a manipulated version of her ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

With social media's history of hyped-up health trends, does a 'Mounjaro drink' drink deliver results - or is it just another internet myth? From 'sleepy girl cocktails' to 'oatzempic' drinks there ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and ... The drugmaker’s stock LLY rose 0.5% in regular trading on Thursday after the company said it ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...

Diabetes drug Mounjaro and weight-loss/diabetes medicine ... Adjusted fourth-quarter profit of $5.32 a share topped the analyst estimate of $5.01 per share. During the quarter, Lilly said it ...

GLP-1 drugs Mounjaro and Zepbound drive a big revenue ... The drugmaker's stock (LLY) rose 0.5% in regular trading on Thursday after the company said it expects to generate an adjusted 2025 ...

Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...